Advances in Brief CDKN 1 A and CDKN 1 B Polymorphisms and Risk of Advanced Prostate Carcinoma 1

@inproceedings{Kibel2003AdvancesIB,
  title={Advances in Brief CDKN 1 A and CDKN 1 B Polymorphisms and Risk of Advanced Prostate Carcinoma 1},
  author={Adam S. Kibel and Brian K. Suarez and Jay S Belani and Joe Oh and Raul Webster and Michele Brophy-Ebbers and Chan Guo and William J. Catalona and Joel Picus and Paul J Goodfellow},
  year={2003}
}
A multigenic model of prostate cancer susceptibility has been proposed, in which common polymorphic variants of genes, such as the androgen and vitamin D receptor, contribute to tumorigenesis. The discovery of additional genetic factors that contribute to prostate cancer risk should provide opportunities for new approaches to the detection and treatment of this common malignancy. Herein, we examined single nucleotide polymorphic variants in the 3 -untranslated region of CDKN1A (p21) and in… CONTINUE READING

3 Figures & Tables

Connections & Topics

Mentioned Connections BETA
These associations were particularly strong in those patients with androgen - independent disease [ OR 2.88 ( 95% CI , 1.19–6.97 ) and 2.11 ( 95% CI , 1.05–4.22 ) for high - risk genotypes of CDKN1A and CDKN1B , respectively ] .
Analysis of CDKN1A and/or CDKN1B genotypes may prove useful in determining which patients are at risk for developing advanced prostate carcinoma and therefore would gain the most from aggressive screening , prophylaxis , and/or treatment .
Herein , we examined single nucleotide polymorphic variants in the 3 -untranslated region of CDKN1A ( p21 ) and in codon 109 of CDKN1B ( p27 ) for association with advanced prostate cancer in a European - American population .
Herein , we examined single nucleotide polymorphic variants in the 3 -untranslated region of CDKN1A ( p21 ) and in codon 109 of CDKN1B ( p27 ) for association with advanced prostate cancer in a European - American population .
Analysis of CDKN1A and/or CDKN1B genotypes may prove useful in determining which patients are at risk for developing advanced prostate carcinoma and therefore would gain the most from aggressive screening , prophylaxis , and/or treatment .
These associations were particularly strong in those patients with androgen - independent disease [ OR 2.88 ( 95% CI , 1.19–6.97 ) and 2.11 ( 95% CI , 1.05–4.22 ) for high - risk genotypes of CDKN1A and CDKN1B , respectively ] .
All Topics